Basking raises $55M; Seroba’s fourth fund; Vera upsizes its public offering

Plus, news about Abeona Therapeutics and Graviton:

Basking Biosciences raises $55M: The Columbus, OH-based startup reeled in funding from half a dozen investors, including ARCH Venture Partners, whose managing director Steven Gillis will join Basking’s board as chair. The biotech plans to start a Phase II for its RNA aptamer BB-031 in patients with acute ischemic stroke this year. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

New research highlights regional variations in COPD prevalence according to diagnostic criteria

The global and regional prevalence of Chronic Obstructive Pulmonary Disease (COPD).

January 30, 2024

Pharmalittle: Europe regulator raised safety signal on Novo drugs; U.S. seeks new trial over royalties on Gilead HIV prevention pills

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will

June 22, 2023

AI uncovers climate change denial hotspots across the US

A University of Michigan study using AI and Twitter data analysis reveals that approximately 15% of Americans deny climate change, with denialism prevalent in Central

February 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.